Haemostasis action of VELSEAL-T in a haemophilia A patient with external bleeding

Open access

Abstract

VELSEAL-Tis an innovative haemostatic medical device for the control of bleeding. Incorporating a clotting agent (thrombin) and anti-fibrinolytic agent (tranexamic acid), it enables rapid coagulation when blood flows into the dressing, leading to sealing and stabilisation of wound surfaces. A 36-year-old known to have mild haemophilia A presented with profuse bleeding from the forehead after injury following a fall on concrete surface. He attended hospital after 18 hours of injury as bleeding continued as soon as pressure was released from the injury site. A VELSEAL-T patch was applied to the injury site with the patient’s full consent. The bleeding stopped after 60 seconds, but the patient was instructed to hold the patch in place for a further 60 seconds. After two minutes of tight pressure application, there was no more oozing of blood from the injury site. This case shows that VELSEAL-T can be used as an aid in stopping external bleeding in haemophilia patients. Further trials should be undertaken to evaluate the safety and efficacy of this product.

1. Skinner MW. WFH: closing the global gap - achieving optimal care. Haemophilia 2012; 18 (Suppl 4): 1-12.

2. Lee CA. Historical introduction. In: Lee CA, Berntorp E, Hoot K, eds.Textbook of Hemophilia, 2nd ed. West Sussex: Wiley- Blackwell, 2010: 1-6.

3. van den Berg HM, Fischer K. Phenotypic - genotypic relationship. In: Lee CA, Berntorp E, Hoots K, eds. Textbook of Hemophilia, 2nd ed. West Sussex: Wiley-Blackwell, 2010: 33-7.

4. Mannucci PM, Tuddenham EG. The hemophilias- from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.

5. Rodeghiero F, Castaman G. von Willebrand disease: epidemiology. In: Lee CA, Berntorp E, Hoots K, eds. Textbook of Hemophilia, 2nd ed. West Sussex: Wiley-Blackwell, 2010: 286-93.

6. Srivastava A, Rodeghiero F. Epidemiology of von Willebrand disease in developing countries. Semin Thromb Hemost 2005; 31: 569-76.

7. Wang XF, Zhao YQ, Yang RC, et al. The prevalence of factor VIII inhibitors and genetic aspects of inhibitors development in Chinese patients with haemofilia A. Haemophilia 2010; 16(4): 632-9.

8. Bitchell TC. Distúrbioshereditários da coagulação. In: Lee GR, Bitchell TC, Foerster J, et al. Wintrobe Hematologia Clinica, vol II, 9th ed. São Paulo: Editora Manole, 1998: 1562-616.

9. da Silva PH, Hashimoto Y. Coagulação:Visão Laboratorial da Hemostasia Primária e Secundária. Rio de Janeiro: Livraria e Editora Revinter, 2006.

10. Giannelli F, Choo KH, Rees DJG, et al. Gene deletions in patients with haemophilia B and antifactor IX antibodies. Nature 1983; 303: 181-2.

11. World Federation of Hemophilia (WFH). Report on the Annual Global Survey 2011. Montréal: WFH; 2013. Available from: http://www1.wfh.org/publications/files/pdf-1488.pdf, accessed 13 November 2017.

12. Kar A, Phadnis S, Dharmarajan S, Nakade J.Epidemiology & social costs of haemophilia in India. Indian J Med Res2014; 140: 19-31.

13. Dutta A, Dutta TS, Kar S, et al. Study on clinical presentation of factor deficient patients presenting to a tertiary care centre of North East India. Journal of Medical Science and Clinical Research 2016; 4(7),doi:

14. Dutta A, Dutta TS, Dey P. Clinical profile of haemophilia patients of upper Assam- a hospital-based study. J Evolution Med Dent Sci 2017;6(37):2990-3, doi:

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 248 248 25
PDF Downloads 85 85 12